Chris Boland - Avivagen CFO

VIV Stock  CAD 0.01  0.00  0.00%   

CFO

Mr. Chris Boland was appointed as Chief Financial Officer of Avivagen Inc., with effect from July 12, 2012 since 2012.
Tenure 12 years
Address 100 Sussex Drive, Ottawa, ON, Canada, K1A 0R6
Phone613-702-2908
Webhttps://www.avivagen.com
Boland is a Canadian chartered accountant and also holds the certified management accountant designation. Prior to his present appointment, Mr. Boland was in public practice . Earlier positions at other organizations include general manager at Canada Post Corporationrationrationration, chief financial officer and vicepresident finance at Optiwave Corporationrationrationration, director of tax and treasury, controller, at Eftia OSS, manager of financial reporting and controller at the Canadian Bank Note, and manager of financial reporting at Mitel Corporationrationrationration. He was also an auditor at the Office of the Auditor General and manager at Treasury Board.

Avivagen Management Efficiency

The company has return on total asset (ROA) of (1.9344) % which means that it has lost $1.9344 on every $100 spent on assets. This is way below average. Avivagen's management efficiency ratios could be used to measure how well Avivagen manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 2.28 in 2024, whereas Return On Assets are likely to drop (4.20) in 2024. At this time, Avivagen's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 2.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 24.1 K in 2024.
The company has accumulated 810.28 K in total debt. Avivagen has a current ratio of 2.87, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Avivagen until it has trouble settling it off, either with new capital or with free cash flow. So, Avivagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Avivagen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Avivagen to invest in growth at high rates of return. When we think about Avivagen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CFO Age

David WatsonMedical Facilities
58
Scott MorstadMedical Facilities
N/A
Michael SalterMedical Facilities
66
Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animals own health defenses. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. AVIVAGEN INC operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on TSX Venture Exchange. It employs 13 people. Avivagen (VIV) is traded on TSX Venture Exchange in Canada and employs 16 people. Avivagen is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Avivagen Leadership Team

Elected by the shareholders, the Avivagen's board of directors comprises two types of representatives: Avivagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avivagen. The board's role is to monitor Avivagen's management team and ensure that shareholders' interests are well served. Avivagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avivagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tracy BVSC, Director Manager
David Hankinson, Executive Director
Louis Hui, Director - Business Development
Chris Boland, CFO
David Allan, Director
Ira Levy, Interim Officer
Amin Khalifa, Independent Director
Aubrey Dan, Director
Cameron Groome, CEO and President and Director
Vanessa Grant, Director
Andrew Basek, Director of Investor Relations
Drew Basek, Director of Investor Relations
Paul Mesburis, Lead Director
James Nickerson, President Innovation
Graham Burton, Co-Founder, Director of Commercialization Science and Director
G Anthony, Independent Director

Avivagen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avivagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Avivagen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Avivagen Stock analysis

When running Avivagen's price analysis, check to measure Avivagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avivagen is operating at the current time. Most of Avivagen's value examination focuses on studying past and present price action to predict the probability of Avivagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avivagen's price. Additionally, you may evaluate how the addition of Avivagen to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Please note, there is a significant difference between Avivagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Avivagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avivagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.